SOAT1 and psoriasis: Tofacitinib inhibits intracellular JAK/signal transducers and activators of transcription (STAT) signaling pathways, both of which play a role in pro-inflammatory effects of many cytokines that are also present in AD and psoriasis (Clarysse et al., 2019; O'Shea and Murray, 2008; O'Shea et al., 2015).